| Assessment Status | Rapid Review Complete |
| HTA ID | 23079 |
| Drug | Sacituzumab govitecan |
| Brand | Trodelvy® |
| Indication | Sacituzumab govitecan is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. |
| Assessment Process | |
| Rapid review commissioned | 21/12/2023 |
| Rapid review completed | 26/01/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sacituzumab govitecan compared with the current standard of care. |